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ABSTRAK 
 
Asma adalah salah satu masalah kesehatan utama di dunia. Gejala asma yang sebenarnya 
dapat diobati dan dikendalikan, sehingga kebanyakan pasien dapat mencegah timbulnya 
gejala sepanjang hari, untuk mencegah serangan yang serius.Apoteker perlu memainkan 
perannya dalam pharmaceutical care (pelayanan kefarmasian) yang bertujuan untuk 
menemukan sistem perawatan kesehatan yang diperlukan untuk meningkatkan nilai terapi 
obat kompleks dan signifikan obat morbiditas dan mortalitas terkait, berfungsi 
untukmeningkatkan hasil farmakoterapi dan kualitas hidup pasien dengan asma. Persepsi 
pasien terhadap kesehatan dan penyakit dan perilaku terkait juga sangat penting untuk 
efektifitas perawatan farmasi. Penelitian ini bertujuan untuk mempelajari peran apoteker 
dalam perawatan farmasi dalam pengobatan rawat jalan asma bronkial. Jenis penelitian adalah 
cross-sectional. Jumlah responden adalah 22 pasien. Dalam data penelitian diperoleh 
dengan wawancara langsung  untuk mengumpulkan data, disertai dengan pengamatan dari 
pasien. Pasien yang terlibat dalam penelitian ini adalah 22. Jumlah drug-related problems 
(DRPs) adalah 20 kasus (problem-based) dan 23 kasus (caused-based). Kelas obat 
yangmenyebabkan DRPs terbanyak adalah beta-2 agonis. Persepsi subjektif dari gejala yang 
dialami oleh sebagian besar pasien dengan asma adalah: sesak napas (100%), 
suaramengi (90%), kelelahan dan kesulitan tidur (85%). Aspek kognitif penyakit yang 
dirasaka oleh pasien mengenai identitas, penyebab penyakit dan menyembuhkan atau 
mengendalikan adalah benar, tetapi mereka tentang konsekuensi dan timeline masih kurang. 
Penelitian ini menunjukkan bahwa peran apoteker dalam perawatan farmasi pada pasien 
asma rawat jalan memiliki sifat konseling langsung ke pasien 
danpemantauan. Pemantauan pasien secara teratur dan analisis terjadinya DRPs untuk 
membantu pasien mendapatkan efektif, pengobatan yang aman dan rasional. 
 
Kata kunci: asma, pelayanan kefarmasian, drug-related problems, persepsi sakit  
 
ABSTRACT 
 
Asthma is one of the major health problems in the world. Actual asthma symptoms can be 
treated and controlled, so that most patients can prevent the onset of symptoms throughout the 
day, to prevent a serious attack. Pharmacists play a role in pharmaceutical care that aims to 
find health care system needed to improve drug therapy of complex and significant value of 
drug-related morbidity and mortality, functions to improve pharmacotherapy outcomes and 
quality of life of patients with asthma. The patient's belief about health and illness and related 
behaviors are also very important to the effectiveness of pharmaceutical care. Objective 
research to study the role of pharmacists in pharmaceutical care in the treatment of outpatient 
asthma bronchiale. The type of study was cross-sectional. The number of respondents 
recruited was 22 patients. In this study data were obtained by direct interview using a form of 
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data collection, accompanied by observations of the patients. Patients involved in this study 
were 22. The total numbers of DRPs were 20 cases (problem-based) and 23 cases (cause-
based). The class of drugs causing most DRPs was beta-2 agonist. The subjective perceptions 
of symptoms experienced by the majority of patients with asthma were: shortness of breath 
(100%), wheezing sound (90%), fatigue and difficulty sleeping (85%). The cognitive aspect 
of illness perceived by the patients regarding identity, cause of illness and cure or control was 
correct, but those concerning consequences and timeline were still lacking. This study 
demonstrates that the role of pharmacists in pharmaceutical care in ambulatory asthma 
patients has a nature of direct counseling to patients and monitoring. Monitoring of patients 
on a regular basis and analysis of the occurrence of drug-related problems might help the 
patients to get effective, safe and rational treatment. 
 
Keywords : asthma, pharmaceutical care, drug related problems, illness perception 
 
INTRODUCTION 
 
Asthma is still one of the major health 
problems in the world.1 Although new drugs 
and evidence-based guidelines have been 
developed in recent years, but no major 
changes in morbidity and mortality asma.2 
Guidelines for the treatment of asthma 
recommend the involvement of patients 
greater role in their treatment.3  
 
According to data from WHO (World Health 
Organization), at 15 million people 
experience disability-adjusted life years 
(DALYs) annually due to asthma, 
representing 1% of the total disease burden 
global.1 SKRT (Survei Kesehatan Rumah 
Tangga) also states that asthma including 10 
major causes of morbidity and mortality in 
Indonesia.  
 
In 1986, SKRT found that asthma and COPD 
(chronic obstructive pulmonary disease) 
ranked 5th out of 10 causes of morbidity. 
SKRT’s data in 1992, asthma and COPD is 
the 4th leading cause of death (mortality). 
While in 1995, the prevalence of asthma of 
13/1000, compared with chronic bronchitis 
and obstructive lung 11/1000 2/1000.4  
 
The National Asthma Education and 
Prevention Program (NAEPP) defines 
asthma as a chronic inflammatory disorder of 
the airways in which many cells and cellular 
elements play a role. In individuals with 
asthma, inflammation causes recurrent 
episodes of wheezing, shortness, chest 
thightness, and cough.1  
 
Actual asthma symptoms can be treated and 
controlled, so that most patients can prevent 
the onset of symptoms throughout the day, to 
prevent a serious attack.4 In the patients with 
asthma treatment, pharmacists play a role in 
pharmaceutical care. Elkhansa Abdelhamid 
et al. research on pharmaceutical care in 
hospitals of patients with asthma, in the 
Shaab Teaching Hospital in Sudan. In this 
study using a prospective method, 
randomized sampling, controlled study 
involving 100 patients with asthma (the 
intervention group (60) and control group 
(40)), the study concluded that the 
intervention of the pharmacist in 
pharmaceutical care can have a positive 
effect on asthma-related outcomes on 
pasien.5 
 
The practice of pharmaceutical care aims to 
find health care system needed to improve 
drug therapy of complex and significant 
value of drug-related morbidity and mortality 
caused by the drug used.6 Therefore, the 
introduction of pharmaceutical care is needed 
in developing countries to increase the 
resolution of problems drug related (drug 
related problems / DRPs).7  
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DRPs can lead to unwanted outcomes that 
increase morbidity and mortality. Bootman 
(2007) examined outcomes in outpatient 
DRPs caused in the United States. Results of 
outcomes caused DRPs found that patients 
who have failed therapy (23%), patients who 
are experiencing new medical problems 
(11%), patients who have failed therapy and 
new medical problems (7%), patients 
receiving drug therapy at least of experience 
one DRPs (>40%).7 Pharmaceutical care can 
be an appropriate strategy to prevent and 
control morbidity and mortality caused 
DRPs.8  
 
Pharmaceutical care functions to improve 
pharmacotherapy outcomes and quality of 
life of patients. Therefore, pharmacists need 
to carry out its role in pharmaceutical care to 
assess the presence of drug-related problems 
(DRPs) in the treatment of patients,9 with 
identifying and correcting potential causes 
that caused the problem in 
pharmacotherapy,10,11 to prevent and control 
drug-related morbidity and mortalitas.6  
 
Procedures to identify and intervene in actual 
and potential DRPs, done with the awareness 
that all the drug at risk of DRPs is an 
important element of drug therapy and can 
contribute to reducing morbidity and 
mortality. Optimization of therapy by 
preventing DRPs will affect health care costs, 
potentially saving lives and improving 
quality of life pasien.12 
 
Self-management of asthma can reduce the 
incidence and improve the quality of life of 
pasien.13,14 The ability of self-management 
should be developed through patient 
education about asthma therapy by health 
accuracy. Pharmacists can provide education 
by providing information on asthma 
treatment, demonstrate how to use inhaled 
medications and peak flow meters, helping 
patients to understand their asthma 
management plan, and monitor the use 
pengobatan.15 
 
DRPs that have been analyzed data can be 
used as an illustration in providing CIE 
(Communications, Information, and 
Education) in patients with asthma according 
to the pharmaceutical care. Understanding 
the patient's belief about health and illness 
and related behaviors are very important to 
the effectiveness of pharmaceutical care.16  
 
In Germany, Schulz et al. Conducting a study 
on 173 patients (intervention group of 101 
patients and control groups were 63 patients). 
Peak flow rate values higher achieved in the 
intervention group after 6 months, but not at 
12 months. However, inhaler technique, 
medication knowledge, and quality of life 
was higher in the intervention group after 12 
months.2 Maltese studies report that 
community pharmacy based asthma 
education program checkers monitoring has a 
positive effect on quality of life, peak 
expiratory flow values, inhalation technique, 
adherence to therapy and the number of 
patients who entered the house sakit.17  
 
This research aims not only to know what 
can happen DRPs in patients with asthma 
outpatient (patients with asthma who have 
chronic asthma therapy), and also know the 
perception of asthma patients to asthma and 
asthma treatment she had received, including 
consequences, timeline, personal control, 
treatment control, identify, concerns, 
emotions, and illness comprehensibility.18 So 
by knowing the DRPs and the perception of 
asthma patients, it can be used as a strategy 
for the preparation of an IEC to achieve 
optimal asthma treatment. 
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METHOD 
 
 This research method is descriptive 
analytic study which is a non experimental 
cross sectional (for drug-related data 
collection problems (DRPs) outpatients at the 
hospital) that is the way data is collected at a 
single time point only. 
 
Identification Research Variable 
 
Depending variable consists of drug-related 
problems (DRPs), the causes of DRPs and 
the perceptions of patients to disease and 
asthma treatment. Free variables consist of: a 
history of previous illness, the results of 
laboratory tests, drugs therapy. Controlled 
variables consisted of asthma patients who 
undergo outpatient treatment in respiratory 
polychlinic Adi Husada Undaan Wetan 
Hospital, Surabaya. 
 
Population and Sample 
 
The study population was patients with 
asthma who are undergoing outpatient 
treatment and meet the criteria for research, 
in hospitals (in clinical medicine) during the 
study. 
 
Samples are asthma patients who are 
undergoing outpatient treatment and fulfilled 
the criteria, can be found by investigators and 
were willing to be a sample of research, in 
hospitals (in clinical medicine) during the 
study.  
 
Inclusion criteria for the outpatient sample: 
(1) Patients asthma with aged 18 years and 
came to the polychlinic in Adi Husada 
Undaan Wetan Hospital to undergo 
outpatient treatment during the study, (2) 
Patients who are willing to participate in the 
research sample. Criteria exclusion (for the 
perception of asthma):18 women 
pregnant/lactating, patients who have other 
respiratory diseases (such as chronic 
obstructive pulmonary disease/COPD, 
emphysema, tuberculosis/TB), patients with 
mental disorders, patients with hearing loss. 
 
Data Collection 
 
In this study data were obtained by direct 
interview using a form of data collection, 
accompanied by observations of the patient.   
 
RESULT AND DISCUSSION: 
 
RESULT 
 
Research to obtain data of patients with 
asthma outpatient (chronic asthma) was 
undertaken during November 16th, 2010 until 
January 15th, 2011 against asthma patients 
who undergo outpatient treatment at the 
Hospital. The number of respondents 
(sample) collected by 22 people, of the total 
population of the study as many as 23 people 
in which researchers found when respondents 
came to the clinic treatment of disease in  the 
hospital. One person cannot be used as a 
sample of the research because it is not 
treated at the clinic when researchers are not 
in place. The sex of the study sample 
consisted of 10 male sex (45%) and 12 are 
female (55%). Age of the study sample 
varied with sample minimum age 19 years 
and maximum age of 70 years of research 
samples. The average age of the study 
sample was 35,10 years. Of the 22 samples 
studies suffer from asthma 45.44% between 
11-20 years; 22.73% for more than 20 years; 
22.73% between 2-5 years, 4.55% between 
6-10 years, and 4.55 % for less than one year. 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma 
Primary Domain of 
DRPs based The 
Problems  
Problems Recomendation Frequency Percent (%) 
Treatment 
effectiveness  
 
Effect of 
drug 
treatment 
not optimal  
 
Theophylline as a therapy of 
chronic asthma. Data from 
theophylline effectiveness as 
long-term controller is still 
lacking, and still have a small 
effect as the controller's first 
choice. And its effectiveness is 
smaller than LABA (long acting 
B2 agonist), so theophylline used 
as additional therapy when 
symptoms of asthma has not been 
controlled with inhaled 
glucocorticosteroids. 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance with 
the guidelines. 
4 5 25 
The use of NSAIDs (ketoprofen) 
in patients with asthma can cause 
asthma exacerbations, although 
it’s a individual effect. 
1 
Untreated 
indication  
 
Not getting treatment as a 
reliever. Reliever used in all stage 
of  chronic asthma therapy as a 
rapid bronchoconstriction in 
acute symptoms, so it’s needed 
all patients with asthma on 
chronic asthma therapy. 
1 5 25 
Not getting antiplatelet in patients 
with hypertension. Antiplatelet as 
primary prevention to prevent 
cardiovascular risk, including 
people with age> 40 years or who 
have additional risk factors 
(family history of CVD, 
hypertension, smoking, 
dyslipidemia, or albuminuria. 
2 
Not getting lipid drug (Statins) in 
patients with hypertension, in 
which statins work to CVD 
outcomes in patients. In patients 
with chronic diseases such as 
diabetes mellitus also have an 
increased lipid abnormalities, 
which can contribute to the risk 
factors of CVD. 
2 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma(continue) 
Primary Domain of 
DRPs based The 
Problems  
Problems Recomendation Frequency Percent (%) 
Adverse 
Reaction 
Adverse 
drug event 
(non-
allergic) 
Fatigue because of losartan (ARB). 
Losartan, one of which is used by 
asthma patients in this study, serves 
as a less risky antihypertensive ARBs 
(Angiotensin Receptor Blocker). Is a 
non-peptide antagonist losartan, 
competitive and selective angiotensin 
II receptor. Mechanism of action of 
losartan is a reversible binding with 
AT1 and AT2 receptors and by 
blocking the effects of 
vasoconstriction and aldosterone 
secretion of angiotensin II. Fatigue 
arising from the use of losartan is 
possible because the effect of 
inhibition of aldosterone secretion. If 
too large decreases the secretion of 
aldosterone, fluid and electrolyte 
balance will be disturbed and 
manifestations that often appear 
among other kelelahan. 
Conduct regular 
monitoring and 
implementation of 
the CIE to the 
patient. 
1 3 15 
Dizziness due to the use of salbutamol 
(short-acting B2 agonist). 
ADR in the form of dizziness caused 
by salbutamol likely caused by 
smooth muscle relaxing effect of 
salbutamol. Relaxation effect arises 
because β2 receptor stimulation. 
Receptor β2 not only found in the 
respiratory tract but also found in 
bone and muscle blood vessels of the 
heart. Excessive stimulation of β2 
receptors (mainly located in vascular 
smooth muscle of the heart) will 
cause vasodilating blood vessels in 
the heart that can cause a decline in 
blood pressure. Manifestations that 
arise from decreased blood pressure is 
one of them is a headache. 
1 
Dry mouth because of salbutamol 
(short-acting B2 agonist) 
1 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma(continue) 
Primary Domain of DRPs 
based The Problems  Problems Recomendation Frequency 
Percent 
(%) 
Treatment 
Costs 
Drug 
treatment 
more costly 
than 
necessary  
 
Formoterol (long acting B2 agonist) 
was used as a reliever. Salbutamol is 
used in the treatment of asthma 
because of the effects of rapid 
bronchodilating, making it suitable 
for use in the event of an acute attack 
and is the drug of choice for asthma 
attacks. 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance 
with the 
guidelines. 
3 3 15 
Others Drug interactions between Diltiazem 
(calcium channel blocker) and 
Theofilin (Potential) 
Perform regular 
monitoring of 
patients. 
1 4 20 
Drug interactions between 
Salbutamol (short acting B2 agonis) 
dan Theofilin (Potensial) 
2 
Salbutamol (short-acting B2 agonist) 
as a reliever that is used is the oral 
form (Actual) 
1 
TOTAL    20 100 
 
 
A controlled asthma is asthma in which 
symptoms of shortness of breath, wheezing, 
coughing, etc. can be removed so as not to 
interfere with activity so that patients can 
move normally. Spirometry and Peak Flow 
Meter can help to diagnose asthma and assess 
the control asma.1,19 Based on interviews 
with outpatient asthma patients, 45,45% 
claim to be obedient in taking the medicine 
according to doctor's instructions so that his 
asthma control, 9,09% said no obedient in 
using the medicine so often symptoms occur, 
while 45,05% did not know. 
 
Of 22 samples of the study patients who say 
they adhere to the use of medication as many 
as 10 peoples (45.45%), and 2 (9.09%) said 
they had low adherence (non-adherent) to the 
treatment. Stage asthma based on outpatient 
treatment received by patients when 
interviewed by investigators, according to 
Global Initiative for Asthma in 2009. It is 
shown variations in the sample experienced 
asthma stage of research. Most of the 
research sample is at stage 1 (68,18%). 
Followed by in stage 3 (13,64%), in stage 2 
(9,09%),  unknown (9,09%), and  in stage 4 
and 5 (0%). Two study samples were 
classified as stage unknown because of 
asthma medication used could not be 
classified under the Global Initiative for 
Asthma in 2009. 
 
Third ADRs caused by salbutamol and 
losartan are said to be actual because it 
appears the clinical manifestations in patients 
with asthma. To support this allegation 
Naranjo scale used to ascertain whether the 
clinical manifestations that emerges is the 
ADRs or not. From the calculation Naranjo 
scale, both drugs provide the same value of 4 
that are interpreted as possible ADRs 
(possible ADRs). The evidence to support 
this allegation was not so strong because of 
limitations in this study is the limited amount 
of research samples and data obtained based 
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on the patient's memory so that there are 
some data that cannot be obtained. 
 
According to Odgen (2007), cognitive 
perception of pain is a picture of the patient 
against disease by identifying five 
dimensions,24 the identity, consequences, 
cause of illness, timeline, and cure or control. 
The results showed that the subjective 
perception of symptoms experienced by the 
majority of patients with asthma are: 
shortness of breath (100%), wheezing sound 
arises (90%), fatigue and difficulty sleeping 
(85%). According to Elaine N. Marieb 
(2004), if there is disorder of the airways or 
excess mucus production can lead to 
wheezing sounds (Whistling sound), this 
shows the difficulty in breathing and 
wheezing sound associated with asthma. If 
there is difficulty in breathing, the body's 
cells deficient supply of oxygen, which 
causes the body becomes tired. Sore throat 
have also been associated with disease 
asma.25 
 
Patient Perceptions Regarding Impact and 
Results of Diseases (Consequences) showed 
that most patients (65%) answered asthma 
affects the activity. In fact, patients with 
asthma do have limitations in activity. 
Therefore, if it has been known to any 
activity which may cause asthma, patients 
should be given counseling prior to taking 
the medicine as prevention of attacks asma.1 
If patients rarely take medicine, using 
inhalers in the wrong way, and improper 
dosage can trigger asthma attack so as to 
provide impact and results deteriorate if not 
treated immediately. Thus, should 
immediately be referred to the hospital. 
 
Patient Perceptions Regarding the causes of 
disease (Cause of Illness) showed that the 
three top factors that cause disease in a row 
their asthma is heredity, environmental 
pollution, and patterns/eating habits.  
Heredity/genetics is a family disease history 
of patients who had suffered from asthma. 
Heredity/genetics it is one of the dominant 
causes of asthma. Environmental pollution 
consisting themselves of cigarette smoke, 
motor vehicle fumes, factory smoke, and free 
radicals is one of the causes of the attacks 
asma.1 Perceptions of Patients Against 
Asthma How Long Will Lasts (Timeline) 
indicates that only a few patients (8 of 20 
people) who know the disease of asthma will 
last forever. 10% of patients respond within 
days and 20% of patients respond within a 
few years of his asthma disease will be cured. 
Many of them do not yet know that his 
asthma disease can occur at any time and not 
unexpected. The rest are those who do not 
know/doubtful (30%) in the answer. Asthma 
do not know the word "cured", because it is 
not curable and can arise at anytime.1 
 
Treatment for asthma therapy are classified 
as a reliever or controller. Reliever is a 
medication that is used when necessary that 
is fast to reduce bronchoconstriction and 
reduce acute symptoms that accompany it. 
While the Controller is a medication that is 
used daily in the long term to keep asthma 
under clinical control over the effect of anti 
inflamasinya.1 Perceptions Regarding the 
Treatment of Patients Can Help The disease 
(Cure or Control) showed that most patients 
(15 of 20 patients) said the disease asthma is 
controlled. 
 
There is a patient believes that the 
medication used to help overcome his asthma 
attacks (15 of 20 people). While the data 
indicated the majority of patients experience 
frequent asthma symptoms in 1-2 times a 
month (10 of 20 people). This is one feature 
of control asthma.1 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma 
Primary Domain of 
DRPs based The 
Problems  
Problems Recomendation Frequency Percent (%) 
Treatment 
effectiveness  
 
Effect of 
drug 
treatment 
not optimal  
 
Theophylline as a therapy of 
chronic asthma. Data from 
theophylline effectiveness as 
long-term controller is still 
lacking, and still have a small 
effect as the controller's first 
choice. And its effectiveness is 
smaller than LABA (long acting 
B2 agonist), so theophylline used 
as additional therapy when 
symptoms of asthma has not been 
controlled with inhaled 
glucocorticosteroids. 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance with 
the guidelines. 
4 5 25 
The use of NSAIDs (ketoprofen) 
in patients with asthma can cause 
asthma exacerbations, although 
it’s a individual effect. 
1 
Untreated 
indication  
 
Not getting treatment as a 
reliever. Reliever used in all stage 
of  chronic asthma therapy as a 
rapid bronchoconstriction in 
acute symptoms, so it’s needed 
all patients with asthma on 
chronic asthma therapy. 
1 5 25 
Not getting antiplatelet in patients 
with hypertension. Antiplatelet as 
primary prevention to prevent 
cardiovascular risk, including 
people with age> 40 years or who 
have additional risk factors 
(family history of CVD, 
hypertension, smoking, 
dyslipidemia, or albuminuria. 
2 
Not getting lipid drug (Statins) in 
patients with hypertension, in 
which statins work to CVD 
outcomes in patients. In patients 
with chronic diseases such as 
diabetes mellitus also have an 
increased lipid abnormalities, 
which can contribute to the risk 
factors of CVD. 
2 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma(continue) 
Primary Domain of 
DRPs based The 
Problems  
Problems Recomendation Frequency Percent (%) 
Adverse 
Reaction 
Adverse 
drug event 
(non-
allergic) 
Fatigue because of losartan (ARB). 
Losartan, one of which is used by 
asthma patients in this study, serves 
as a less risky antihypertensive ARBs 
(Angiotensin Receptor Blocker). Is a 
non-peptide antagonist losartan, 
competitive and selective angiotensin 
II receptor. Mechanism of action of 
losartan is a reversible binding with 
AT1 and AT2 receptors and by 
blocking the effects of 
vasoconstriction and aldosterone 
secretion of angiotensin II. Fatigue 
arising from the use of losartan is 
possible because the effect of 
inhibition of aldosterone secretion. If 
too large decreases the secretion of 
aldosterone, fluid and electrolyte 
balance will be disturbed and 
manifestations that often appear 
among other kelelahan. 
Conduct regular 
monitoring and 
implementation of 
the CIE to the 
patient. 
1 3 15 
Dizziness due to the use of salbutamol 
(short-acting B2 agonist). 
ADR in the form of dizziness caused 
by salbutamol likely caused by 
smooth muscle relaxing effect of 
salbutamol. Relaxation effect arises 
because β2 receptor stimulation. 
Receptor β2 not only found in the 
respiratory tract but also found in 
bone and muscle blood vessels of the 
heart. Excessive stimulation of β2 
receptors (mainly located in vascular 
smooth muscle of the heart) will 
cause vasodilating blood vessels in 
the heart that can cause a decline in 
blood pressure. Manifestations that 
arise from decreased blood pressure is 
one of them is a headache. 
1 
Dry mouth because of salbutamol 
(short-acting B2 agonist) 
1 
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Table 1. The types of DRPs Based on Problems in Sample with Chronic Asthma(continue) 
Primary Domain of DRPs 
based The Problems  Problems Recomendation Frequency 
Percent 
(%) 
Treatment 
Costs 
Drug 
treatment 
more costly 
than 
necessary  
 
Formoterol (long acting B2 agonist) 
was used as a reliever. Salbutamol is 
used in the treatment of asthma 
because of the effects of rapid 
bronchodilating, making it suitable 
for use in the event of an acute attack 
and is the drug of choice for asthma 
attacks. 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance 
with the 
guidelines. 
3 3 15 
Others Drug interactions between Diltiazem 
(calcium channel blocker) and 
Theofilin (Potential) 
Perform regular 
monitoring of 
patients. 
1 4 20 
Drug interactions between 
Salbutamol (short acting B2 agonis) 
dan Theofilin (Potensial) 
2 
Salbutamol (short-acting B2 agonist) 
as a reliever that is used is the oral 
form (Actual) 
1 
TOTAL    20 100 
 
 
DISCUSSION 
 
Drug groups causing most DRPs are a B2 
agonist drug class. B2 agonist serves as a 
reliever that is used in every stage chronic 
asthma therapy as a rapid 
bronchoconstriction in acute symptoms,1 so 
the reliever (e.g. salbutamol) is required by 
all asthma patients in chronic asthma therapy.  
The five dimensions above have revealed a 
wide range of patient pain perception. 
Perception of pain patients about identity, 
cause of illness, and cure or control is right, 
while on the Consequences and the timeline 
is still lacking. By knowing a person's 
perception of his illness, the pharmacist in 
Pharmaceutical Care to do the counseling, 
information, and education (CIE) regarding 
knowledge about asthma and its treatment in 
order to achieve optimal drug therapies that 
improve the quality of life of patients. It can 
also be developed efforts of health promotion 
strategies and approaches that are good for 
reducing the number of patients affected by 
asthma attacks. 
  
The implementation of the necessary 
pharmaceutical planning to be done on an 
outpatient: 
1. Against other health personnel (doctor) to 
discuss appropriate treatment in 
accordance with the Global Initiative for 
Asthma Guidelines (2009). 
2. Implementation of CIE of patient-related: 
a. Compliance with drug use 
b. Recognizing the signs of drug side 
effects of the most mild and common, 
to the heavy 
c. Recognize the patient's asthma control 
condition 
d. Recognizing the triggers for each 
patient 
 
Need to conduct further research related to 
pharmaceutical care practice in asthma 
patients, asthma patients both outpatient and 
inpatient in order to serve as the evaluation 
and improvement of pharmaceutical care 
practice widely. 
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Table 2. The types of DRPs Based on Causes in Sample with Chronic Asthma 
Primary Domain of 
DRPs based The Causes  Causes 
Recomendatio
n 
Frequency Percent (%) 
Drug 
Selection 
Innapropiate 
drug  
The use of NSAIDs (ketoprofen) in 
patients with asthma can cause 
asthma exacerbations, although 
ersifat individual. 
 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance 
with the 
guidelines. 
1 1 4.35 
Drug 
interaction 
Drug interactions between 
Diltiazem (calcium channel 
blocker) and Theofilin (Potential).  
Drug interactions between 
Diltiazem and Theophylline 
potentially occur. Giving calcium 
channel blockers to patients using 
theophylline are normally not 
caused adverse effect on asthma 
control, although the smallest 
changes can occur at serum levels 
of theophylline. The mechanism of 
this interaction is believed that 
diltiazem can decrease theophylline 
metabolism in the liver, possibly by 
inhibition of P450 isoenzyme 
cyctochrome CYP1A2. 
Perform 
regular 
monitoring of 
patients. 
1 3 13.04 
Drug interactions between 
salbutamol (short-acting B2 
agonist) and Theofilin (Potential).  
Drug interactions between 
salbutamol (B2Agonis) and 
Theofilin potentially occur. The use 
of theophylline and beta-agonists 
and useful for asthma therapy, but 
the potentiation of adverse effects 
may occur, the most serious 
condition is the occurrence of 
hypokalemia and tachycardia, 
especially in the use of high doses 
of theophylline. Securities that can 
happens is the effect on heart rate 
or levels of potassium. B2 agonists 
can cause hypokalemia especially 
when given parenterally or 
nebulized. Effect of potassium level 
decrease of drug interactions is not 
diketahui. 
2 
 
  
Pharmacist’s Strategies In Treating Asthma Bronchiale Outpatient 
 
J. Trop. Pharm. Chem. (Indonesia). 2011. Vol 1. No. 3.  189 
 
Table 2. The types of DRPs Based on Causes in Sample with Chronic Asthma 
Primary Domain of 
DRPs based The Causes  Causes Recomendation Frequency 
Percent 
(%) 
Drug 
Selection 
More  cost-
effective 
drug 
available 
Formoterol (long acting B2 
agonist) was used as a reliever  
Discuss with 
doctor about 
appropriate 
treatment in 
accordance with 
the guidelines. 
1 7 30.43 
Theophylline as a therapy of 
chronic asthma 
4 
Fenoterol (long acting B2 agonist) 
was used as a reliever  
2 
Synergistic/p
reventive 
drug required 
and not given  
Not getting treatment as a reliever  1 5 21.74 
Not getting antiplatelet in patients 
with hypertension 
2 
Not getting your lipid drug 
(Statins) in hypertensive patients 
2 
Drug 
Form 
Inappropriate 
drug form  
 
Ketoprofen (NSAIDs) are used as 
an analgesic. The use of NSAIDs 
(ketoprofen) in patients with 
asthma can cause asthma 
exacerbations, although the nature 
individual. therefore more secure 
if the use of NSAIDs in the 
topical form not systemic. 
Discuss with 
doctor about 
appropriate 
treatment in 
accordance with 
the guidelines. 
1 2 8.70 
Salbutamol (short-acting B2 
agonist) as a reliever that is used 
is the oral form. Salbutamol is 
indicated for reliever should not 
be used in oral form, but are 
inhaled. This is because the 
benefits from the use of 
inhalation, where the effects to the 
respiratory tract will be faster, and 
the concentrations were relatively 
smaller than that of systemic side 
effects that can be generated 
relatively more kecil. 
1 
Patient Patients forget to use / consume drugs Implementation 
of CIE 
2 2 8.70 
Others  Fatigue because of losartan 
(ARB) (Actual) 
Conduct regular 
monitoring and 
implementation 
of the CIE to the 
patient. 
1 3 13.04 
Dizziness due to the use of 
salbutamol (short-acting B2 
agonist) (Actual) 
1 
Dry mouth because of salbutamol 
(short-acting B2 agonist) (Actual) 
1 
TOTAL    23 100 
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CONCLUSION AND SUGGESTION 
 
The role of pharmacists in pharmaceutical 
care in ambulatory asthma patients is a direct 
counseling to patients and monitoring the use 
of medications for ambulatory (able to use 
PMRs/Patient Medication Records). 
Monitoring treatment of patients on a regular 
basis and analyze the occurrence of drug-
related problems that would/could/have been 
experienced by patients taking optimal 
treatment, effective, safe and rational. 
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